UCB Ventures
VC Fund
Brussels, Belgium
UCB Ventures is a €150 million strategic corporate venture fund
- Total investments:
- 21
- Last investment:
- Lead investor:
- 38%
Last updated:
For AI agents: llms.txt
Industries UCB Ventures invests in
Stages UCB Ventures invests in
Countries UCB Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $1.8M–$3.5M
- Series A
- $6.6M–$75M
- Series B
- $9.4M–$135M
Investment Focus
Industry
- Biotechnology 12 (57%)
- Health Care 7 (33%)
- Medical 5 (24%)
- Therapeutics 5 (24%)
- Life Science 4 (19%)
Stage
- Series A 8 (38%)
- Series B 5 (24%)
- Seed 2 (10%)
- Venture - Series Unknown 2 (10%)
- Series E 1 (5%)
Country
- United States 9 (43%)
- Belgium 3 (14%)
- Spain 1 (5%)
- United Kingdom 1 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Alicia Iruzun Lafitte
Partner
|
Partner | Total investments: 4 | Find email | |
Emmanuel Lacroix
Partner
|
Partner | Total investments: 1 | Find email | |
Delphine Hajaji
Partner
|
Partner | Total investments: 0 | Find email | |
Erica Whittaker
Head of UCB Ventures
|
Head of UCB Ventures | Total investments: 9 | Find email | |
Joshua Sands
Principal
|
Principal | Total investments: 0 | Find email | |
| See all 6 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
SonoThera
|
SonoThera is a biotechnology company that creates non-viral genetic therapies using ultrasound. Its mission is to develop genetic medicines that treat the root cause of human disease. SonoThera is expanding the possibilities of disease treatment with ultrasound-guided nonviral gene therapy for diseases with suboptimal or non-existent treatments. Itaims to improve the lives and health of millions of people. | $125M / Series B / Jun 10, 2026 | |
Splice Bio
|
Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases. The company’s platform has the potential to address two existing limitations ofadeno-associated viruses (AAVs), both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted. | $135M / Series B / Jun 11, 2025 | |
Neurona Therapeutics
|
Neurona Therapeutics is a pre-clinical stage biotechnology company that was founded by four neuroscientists and stem cell pioneers at The University of California, San Francisco. They are focused on the discovery and development of cell-based therapies to treat intractable neurological disease. Its initial aim is to generate therapeuticcompositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. Based on nearly two decades of research, they believe that particular subpopulations of neurons have the unique ability to integrate and repair dysregulated neural circuits. Its talented team of scientists, scientific advisors, and board directors is working to accelerate breakthrough treatments for patients with significant unmet medical needs. | $102M / Apr 03, 2025 | |
|
Neurona Therapeutics
|
Neurona Therapeutics is a pre-clinical stage biotechnology company that was founded by four neuroscientists and stem cell pioneers at The University of California, San Francisco. They are focused on the discovery and development of cell-based therapies to treat intractable neurological disease. Its initial aim is to generate therapeuticcompositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. Based on nearly two decades of research, they believe that particular subpopulations of neurons have the unique ability to integrate and repair dysregulated neural circuits. Its talented team of scientists, scientific advisors, and board directors is working to accelerate breakthrough treatments for patients with significant unmet medical needs. | $102M / Series F / Apr 03, 2025 | |
|
Neurona Therapeutics
|
Neurona Therapeutics is a pre-clinical stage biotechnology company that was founded by four neuroscientists and stem cell pioneers at The University of California, San Francisco. They are focused on the discovery and development of cell-based therapies to treat intractable neurological disease. Its initial aim is to generate therapeuticcompositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. Based on nearly two decades of research, they believe that particular subpopulations of neurons have the unique ability to integrate and repair dysregulated neural circuits. Its talented team of scientists, scientific advisors, and board directors is working to accelerate breakthrough treatments for patients with significant unmet medical needs. | $120M / Series E / Feb 08, 2024 | |
ViaNautis
|
Precision Solutions | $24.6M / Series A / Nov 13, 2023 | |
Switch Therapeutics
|
Switch Therapeutics is a biotech company that develops RNAi therapies based on technology. The company was founded in 2020 and is based in San Francisco, California, United States. | $52M / Series A / Mar 14, 2023 | |
Code Biotherapeutics
|
Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. Code Bio leverages its novel multivalent synthetic DNA delivery platform, 3DNA, which has been engineered to overcome many of the challenges inherent with viral-basedgene therapies such as immunogenicity, size and delivery limitations, re-dosability, and manufacturing complexity. The company is advancing an internal pipeline focused on select rare disease programs as well as establishing partnerships to take forward programs in both rare and prevalent diseases. | $75M / Series A / Jun 07, 2022 | |
|
Splice Bio
|
Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases. The company’s platform has the potential to address two existing limitations ofadeno-associated viruses (AAVs), both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted. | $56.9M / Series A / Feb 16, 2022 | |
EsoBiotec
|
EsoBiotec is a Belgian biotechnology business focused on the discovery of novel cancer therapies.EsoBiotec's objective is to enable the human body to fight cancer by delivering 'in vivo' cell engineering to patients. | $3.5M / Seed / Sep 30, 2021 | |
| See all 21 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does UCB Ventures invest in?
UCB Ventures invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 21 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is UCB Ventures's check size?
UCB Ventures typically joins rounds of $1.8M–$3.5M at Seed, $6.6M–$75M at Series A and $9.4M–$135M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds UCB Ventures participates in.
How do I contact UCB Ventures?
Public channels for UCB Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at UCB Ventures?
The team at UCB Ventures includes Alicia Iruzun Lafitte (Partner), Emmanuel Lacroix (Partner) and Delphine Hajaji (Partner), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
